Equipment
Effectiveness scores 65 due to mechanistic support from studies like Chellappa (2013) showing blue light impairs NREM slow waves, Tsubota (2021) where blockers preserved deep sleep vs. blue exposure, and Nagare (2019) on ipRGC/melatonin benefits, but tempered by Cochrane (2023) meta-analysis of 17 RCTs finding inconsistent/low-certainty sleep gains in healthy users and no eye strain relief. Safety is perfect (100) as eyewear poses negligible risk, backed by no FDA issues and low adverse rates. Q
ROKA Rory 2.0 offers premium comfort and plausible mechanistic benefits for evening screen use, with positive anecdotal sleep reports. However, clinical evidence is moderate/mixed, favoring specific groups over healthy users. Consider if valuing build quality over cost/basic blockers.